Table 2.
Model parameters: baseline values, ranges, and distributions for sensitivity analysis.
| Parameters | GP | TPF | Distribution |
|---|---|---|---|
| DFS cost, $/cycle | |||
| Cost of treatment | |||
| Gemcitabine | 559.26 (328.92−902.79) | γ | |
| Docetaxel | 764.46 (547.04−1,137.24) | γ | |
| Fluorouracil | 148.40 (80.19−200.48) | γ | |
| Cisplatin | 13.47 (8.38−16.75) | 13.47 (8.38−16.75) | γ |
| Prophylactic leucocyte | 89.86 (71.89−107.83) | γ | |
| Hydration | 53.16 (38.91−68.13) | 49.36 (32.89−69.90) | γ |
| Antiemetic drugs | 82.78 (66.22−99.33) | 82.78 (66.22−99.33) | γ |
| Hospitalization | 115.47 (92.38−138.57) | 96.23 (76.98−115.47) | γ |
| PICC/one time | 235.74 (188.60−282.89) | 347.24 (277.79−416.69) | Cost: γ Rate: β |
| Laboratory test | 108.20 (86.57−129.85) | 119.03 (95.23−142.84) | γ |
| Imaging examination | 201.50 (161.20−241.80) | γ | |
| Radiotherapy | 2,624.40 (2,099.52−3,149.28) | γ | |
| Preparation of radiotherapy/one time | 1,066.24 (852.99−1,279.48) | γ | |
| DFS cost, ($)/cycle | |||
| Subsequent treatment | 541.36 (433.09−649.63) | 524.08 (419.26−628.89) | γ |
| Best supportive care | 52.53 (42.02−63.04) | γ | |
| Management of AEs/cycle | |||
| Grades 1−2 | 372.42 (124.57−731.95) | 345.50 (117.46−708.22) | γ |
| Grades 3−4 | 655.52 (399.58−1093.12) | 770.69 (296.43−1820.50) | γ |
| Cost of follow-up/cycle | |||
| First 2 years | 147.26 (117.81−176.71) | γ | |
| Years 3−5 | 81.58 (65.27−97.90) | γ | |
| Years 6−10 | 40.79 (32.63−48.95) | γ | |
| Utility | |||
| Utility of DFS | 0.76 (0.61−0.91) | β | |
| Utility of PD | 0.57 (0.46−0.68) | β | |
| Other | |||
| Cost and QALYs discount rate/year | 3% | ||
| Willingness to pay | $31,008.16 (3×per capita gross domestic product) | ||
| Exchange rates | $1 = ¥ 6.8606 (2020.1) http://www.pbc.gov.cn/rmyh/108976/109428/index.html |
||
AE, adverse event; ICER, incremental cost-effectiveness ratio; PICC, peripherally inserted central catheter; QALY, quality-adjusted life-year.